Alpha Cognition initiated with an Outperform at Raymond James
Raymond James analyst Ryan Deschner initiated coverage of Alpha Cognition with an Outperform rating and $20 price target. Alpha Cognition markets Zunveyl, a prodrug of FDA-approved galantamine, which is indicated for the treatment of mild-to-moderate dementia in patients with Alzheimer's disease, the analyst noted. Zun